Video: Nabriva Plans Second Phase III Trial in CABP
Executive Summary
Nabriva Therapeutics discussed plans to use IPO proceeds to complete two Phase III trials of lefamulin in community-acquired bacterial pneumonia, during a recent interview at the Biotech Showcase.